Navigation Links
Patient Safety Authority Issues Annual Report for 2007
Date:4/30/2008

to the facility. In about 13% of reports where MRSA was found upon admission, the information about the infection was not communicated to other healthcare workers. Consumer tips for how the patient can help protect themselves against MRSA were included with this Advisory and have been distributed through other means.

-- Assessed volunteer users of electronic pharmacy systems in Pennsylvania. The study raised awareness that the pharmacy computer systems were not detecting all unsafe drug orders. The Authority encouraged all Pennsylvania facilities to test their systems to ensure all potentially harmful medication errors are caught.

-- Focused attention on the increased risks of anesthesia complications for patients with obstructive sleep apnea (OSA). OSA is a common sleep disorder that causes recurrent episodes of complete and partial airway collapse during sleep, resulting in the failure to breathe properly. Approximately 80-90% of patients with OSA are undiagnosed, but incorporating OSA into pre-surgical screening gives clinicians an opportunity to take steps to reduce anesthesia complications for these patients. Over 250 reports show OSA as a contributing factor for anesthesia complications. About 20% are considered Serious Events, including three deaths.

-- Continued focus on frequency of medication errors highlighting unclear and confusing labeling and packaging, as well as look-alike or sound-alike drug names as potential causes. The Authority offered guidance on how to minimize the risk by using technology such as bar coding and automated dispensing technology; requiring staff to double check the dose before administering; and monitoring patients closely before discharge.

The Authority's research findings are disseminated widely through the Patient Safety Advisories. The importance of distributing the Advisories to all appropriate healthcare facility staff cannot be emphasized enough so that the facility can benefit fully f
'/>"/>

SOURCE Pennsylvania Patient Safety Authority
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Comparison of obstetric outcomes between on-call and patients own obstetricians
3. Vision restoration therapy shown to improve brain activity in brain injured patients
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
8. Study provides hope that some transplant patients could live free of antirejection drugs
9. Study provides hope that some transplant patients could live free of anti-rejection drugs
10. Longer ambulance journeys boost death risk for seriously ill patients
11. Expenses Overshadow Optimism for Kidney Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)... , CHAMPAIGN, Ill. Many older Americans may be s...cial Security too soon, according to a University ...irement program for nearly two decades. , More t...ly Social Security checks for life by claiming ben...tter understood the program,s options and conseque...
(Date:9/4/2008)... Officials want stronger labeling about fungal in...lthDay News) -- Federal health authorities have as...ppressive drugs to bolster safety warnings on the .... , The drugs, Humira, Cimzia, Enbrel and Remic...or necrosis factor alpha blockers (TNF-alpha block...
(Date:9/4/2008)... PACIFIC PALISADES, Calif., Sept. 4 /PRNewswi...r and recognized authority in the field of weight,... "Who,s Who in,California," "Who,s Who in The West...," "Who,s Who in Medicine and Health Care" and oth...evote his expertise to exposing the,inaccurate, mi...
(Date:9/4/2008)... HARRISBURG, Pa., Sept. 4 /PRNewswire-USNewsw...ely 250 individuals, organizations, and community,...Pennsylvania, has added,an interactive map to its ...f the water they drink contains the optimal level ...alf of Pennsylvania,s citizens currently have opti...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 3Health News:Phone World-famed Martin Schiff, M.D., at 310-454-6172 for Free Weight Loss 'No Diet, No Stuff' Method. Hates Diets, Loves to Have People Help Themselves 2Health News:PA Fluoride NOW Debuts Interactive Map for Residents to Learn if Their Water Has the Best Fluoride Level to Protect Teeth 2Health News:PA Fluoride NOW Debuts Interactive Map for Residents to Learn if Their Water Has the Best Fluoride Level to Protect Teeth 3
...0% of youth in the United States cannot boast of a...e case with nearly 15 million// American adults wh...cession. A report from the Agency for Healthcare ...mericans who were not covered under health insuran...
... good trend of decline in the number of suicides. ...realize its goal of scaling down the suicide rates...ealth has enabled some Statistics which portray th... per 100,000 and in 2004 it had dropped to 8.56 de...
...rgos, has confirmed that a new hospital for the Be... Stating that he has directed the Area Health Se...g process for a new hospital. Stating that they wi...future health needs of the Bega community in order...
...’s or KFC restaurants, across the world, have vary...an the levels of the same // food elsewhere. Accor...ew England Journal of Medicine, the researchers an...d's chicken nuggets, KFC hot wings, french fries f...
Other Medicine News:Health News:Construction Of A New Hospital In The Bega Area Confirmed 2
(Date:9/6/2008)...rcent or Greater Concordance Compared to FISH ..., - Company to Include Reporting for HER2 Gene Exp...Reports by End of 2008 -, REDWOOD CITY, Calif., S...nc. (Nasdaq: GHDX ) today announced results from ...ing for HER2 gene expression, as measured by the,c...
(Date:9/5/2008).../PRNewswire-USNewswire/ -- The Florida,Technology,...lorida,Atlantic University researcher Dr. Herbert ... the Center for Molecular Biology and,Biotechnolog...d CHS,Resources LLC (CHS), $184,294 as part of the...tance Grant program (SURECAG). SURECAG was,establi...
(Date:9/5/2008)...., Sept. 5 /- SARcode,Corpo...e LFA-1 inhibitors,to treat inflammatory diseases,...today announced SARcode,s initiation of a Phase 1 ...andidate for T-cell mediated ophthalmic,diseases. ...nt providing,SARcode with an exclusive license to ...
(Date:9/4/2008).... 4 /- Cytopia Limited (ASX:,CYT) tod...ts Phase Ib/II,study of CYT997, the company,s nove...s with an aggressive form of brain cancer known as... trial is the first Phase II efficacy study in hig...any and the second in its,suite of Phase II studie...
Breaking Medicine Technology:Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 2Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 3Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 4Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients 5Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement 4472 1ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement 4472 2Immunosyn Corporation to Present at FSX 1465 1Immunosyn Corporation to Present at FSX 1465 2New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR 28R 29 28zolpidem tartrate extended release 2 633 1New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR 28R 29 28zolpidem tartrate extended release 2 633 2New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR 28R 29 28zolpidem tartrate extended release 2 633 3New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR 28R 29 28zolpidem tartrate extended release 2 633 4A new key to detecting deadly aortic aneurysms 4466 1A new key to detecting deadly aortic aneurysms 4466 2
...tudy Fails to Meet Primary Endpoint of Improvement... 2007 /PRNewswire-FirstCall/ --,Allos Therapeutics...H, the Company,s pivotal Phase 3 study of Efaproxy...y (WBRT) in women,with brain metastases originatin...its primary endpoint of demonstrating a,statistica...
...SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ --...l company committed to,the discovery, development ...reatment of hepatitis and cancer, announced today ...inical development as an,orally-administered direc... C virus (HCV) infection. , "We have identified a ...
Other Medicine Technology:Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 4
Aire-Cuf® and Fome-Cuf® tracheostomy tubes with talk attachment are available in I.D. sizes from 5.0 mm to 9.5 mm. , ,Developed to aid the ventilator dependent patient in communicating with
For additional patient safety, the laryngectomy tube is designed with an integral 15 mm ISO termination that can be connected to a ventilator, with or without the inner cannula in place , ,Portex&re
The all silicone construction of the shaft and neck flange provides the utmost in patient comfort. , ,The Aire-Cuf® tracheostomy tube offers a more traditional and familiar air-filled cuff desig
...® Mid-Range Aire-Cuf® Adjustable Neck Flan...he TTS™ tube except this tube features the m...g;., ,Adult Mid-Range Aire-Cuf® Adjustable Ne...ude a trach tie, disconnect wedge, and obturator/i...
Medicine Products: